Severe Hemophilia A Recruiting Phase 3 Trials for Emicizumab (DB13923)

Also known as: Severe Haemophilia A / Hemophilia A, Severe

IndicationStatusPhase
DBCOND0034640 (Severe Hemophilia A)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04431726A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without InhibitorsTreatment